ADAM7 (A disintegrin and metalloproteinase 7) belongs to the family of zinc-based proteinases, metzincins called ADAM. It is normally not expressed in melanocytes, but is expressed in melanoma cells. It is composed of the "Met turn" and three conserved histidine residues. Its cytoplasmic region contains an Src homology region 3 (SH3)-binding domain and a phosphorylation site. This gene is localized to human chromosome 8p12. In mice, this protein is expressed in the caput region of the epididymis and in the anterior pituitary gonadotropes.
Synonyms: Anti-ADAM metallopeptidase domain 7; Anti-EAPI; Anti-GP-83
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: ADAM7 (A disintegrin and metalloproteinase 7) is one of the most frequently mutated ADAM family member, and is mutated in more than 12% melanoma cases. It does not have protease activity, but is thought to be involved in protein folding and protein-protein interactions.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC